DermaGen AB Report issue

For profit Phase 2
Founded: Lund Sweden (2004)
Status: Acquired by Pergamum AB (2011)

Organization Overview

First Clinical Trial
2008
NCT01522391
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Me3+ Clinical Trials, Gothenburg

Active Ingredients

Drugs in Phase 2 Trials (1)

dpk-060 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Otitis (Phase 2)

Otitis Externa (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1